Abstract
Trazodone (TZ) was administered to nine patients suffering from obsessive-compulsive disorder (OCD), who failed to respond to either clomipramine (CMI) or to CMI plus lithium carbonate. The group, as a whole, showed significant but mild improvement. Three patients responded very favorably to TZ. In these three responders, efficacy was substantiated by the return of original obsessive-compulsive (OC) symptoms following TZ withdrawal and their amelioration after its readministration. Interestingly, the aggravation of OCD symptomatology that has been associated with a specific TZ metabolite was not observed. This study is consistent with previous reports of the anti-OC efficacy of TZ and suggests the involvement of complex serotonergic mechanisms in the pathophysiology of this disorder.
Original language | English |
---|---|
Pages (from-to) | 322-328 |
Number of pages | 7 |
Journal | Clinical Neuropharmacology |
Volume | 13 |
Issue number | 4 |
DOIs | |
State | Published - 1990 |
Externally published | Yes |
Keywords
- Clomipramine
- Lithium carbonate
- Obsessive-compulsive disorder
- Serotonin
- Trazodone